News

A multinational clinical project (OligoG-pivotal-CF) to test the orphan drug OligoG CF-5/20 (OligoG) in a pivotal phase IIb clinical trial for the treatment of cystic fibrosis (CF).

Instructions for Use and Video links now online!

June 16, 2020/in News /by philiprye

The instructions for use and videos on how to take the trial medicine are now available online. Trial participants and care givers can access this information on this website in the “Clinical” trials section on the Resources Page

First site initiation in Austria

May 29, 2020/in News /by philiprye

The OligoGpivotalCF trial is about to start recruiting. On 6th May 2020 the first site was initiated in Wels, Austria and more site initiation visits are planned for the coming months. Pending the normalization of the Covid-19 pandemic, the trial will open for patients at several sites in Europe soon. If you want to know […]

OligoGpivotalCF and Covid-19: AlgiPharma CF Clinical Trial Operations in Europe

March 16, 2020/in News /by philiprye

We have now received regulatory approvals from Austria, UK, Germany and Ireland, and ethics approvals from Austria and UK. Ethics approvals from Germany and Ireland are expected to follow soon in order for us to proceed with the OligoGpivotalCF clinical study. However, due to the current situation with COVID-19, we have decided to postpone site […]

AlgiPharma’s Cystic Fibrosis drug candidate OligoG awarded pivotal trial grant of €6 million from EU’s Horizon 2020 programme

January 15, 2018/in News /by rogerhenriksen

An EU Horizon 2020 proposal (OligoGpivotalCF) submitted by a consortium assembled by AlgiPharma, has been successful in winning a grant of EUR 6 million to support AlgiPharma’s cystic fibrosis drug candidate OligoG through a pivotal clinical trial program.

About the project

OligoG-pivotal-CF is a multinational clinical project to test the orphan drug OligoG CF-5/20 (OligoG) in a pivotal phase 2b clinical trial for the treatment of cystic fibrosis (CF). The project is funded by the H2020-SC1-2017-Two-Stage-RTD, topic SC1-PM-08-2017, and represents a new therapy for the rare disease cystic fibrosis (CF). The study drug OligoG CF-5/20 (OligoG) has received an EU Orphan Drug Medicinal Product Designation in 2007 and an FDA Orphan Drug Designation February 2016, both for the treatment of cystic fibrosis.